Ensysce Biosciences Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent covering its MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof," includes composition-of-matter and method-of-use claims, extending protection for MPAR® through 2042. The technology is designed to provide overdose protection, with clinical trials demonstrating its ability to moderate opioid release when taken in excess.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113613) on December 02, 2025, and is solely responsible for the information contained therein.